Author

A. D. Durbin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:experimental assay· 4 Research Focus:cell type annotation· 3 Research Focus:gene regulatory network inference· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Assay:DNA methylation· 2 Research Focus:drug response / drug discovery· 2

Frequent Co-Authors

A. Berezovskaya· 2 shared A. T. Look· 2 shared B. J. Abraham· 2 shared M. W. Zimmerman· 2 shared S. He· 2 shared S. Nance· 2 shared A. E. Goodspeed· 1 shared D. Currier· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Berezovskaya

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

PRMT5 orchestrates EGFR and AKT networks to activate NFκB and promote EMT

L. Huang, M. Ravi, X.-O. Zhang, O. Verdejo-Torres, N. A. M. Shendy, M. A. M. Nezhady, S. Gopalan, G. Wang, A. D. Durbin, T. G. Fazzio, J. Q. Wu

This study identifies PRMT5's role in promoting EMT in neuroblastoma by regulating EGFR and AKT pathways, leading to NFκB activation and tumor growth.

bioRxiv · Jan 3, 2024 · PreprintCancer Biology

A CRISPR-drug perturbational map for identifying new compounds to combine with commonly used chemotherapeutics.

H.-M. Lee, W. C. Wright, M. Pan, J. Low, D. Currier, J. Fang, S. Singh, S. Nance, I. Delahunty, Y. Kim, R. H. Chapple, Y. Zhang, X. Liu, J. A. Steele, J. Qi, , P. Geeleher

The paper uses CRISPR knockout screens to identify drug combinations that enhance the effectiveness of common chemotherapeutics in neuroblastoma cells.

bioRxiv · Apr 12, 2023Cancer Biology

STAT3 cooperates with the core transcriptional regulatory circuitry to drive MYC expression and oncogenesis in anaplastic large cell lymphoma

N. Prutsch, S. He, A. Berezovskaya, A. D. Durbin, N. V. Dharia, K. Stegmaier, J. D. Matthews, L. Hare, S. D. Turner, L. Kenner, O. Merkel, R. A. Young, B. J. Abraham, A. T. Look, M. W. Zimmerman

This study identifies STAT3's role in driving MYC expression and oncogenesis in ALCL by cooperating with a core transcriptional regulatory circuit.

bioRxiv · Aug 31, 2022 · PreprintCancer Biology

SIX1 Reprograms Myogenic Transcription Factors to Maintain the Rhabdomyosarcoma undifferentiated state

J. Y. Hsu, E. P. Danis, S. Nance, J. O'Brien, V. M. Wessells, A. E. Goodspeed, J. C. Talbot, S. L. Amacher, P. Jedlicka, J. C. Black, J. C. Costello, A. D. Durbin, K. B. Artinger, H. L. Ford

This study shows that SIX1 maintains the undifferentiated state of rhabdomyosarcoma cells by altering MYOD1 activity and enhancer regulation, and a SIX1 loss gene signature predicts RMS progression.

bioRxiv · Apr 25, 2021Cancer Biology

Retinoic acid rewires the adrenergic core regulatory circuitry of neuroblastoma

M. W. Zimmerman, A. D. Durbin, S. He, F. Oppel, H. Shi, T. Tao, Z. Li, A. Berezovskaya, Y. Liu, J. Zhang, R. Young, B. J. Abraham, A. T. Look

This study shows retinoic acid reprograms enhancer landscapes in MYCN-amplified neuroblastoma cells, downregulating MYCN and inducing sympathetic differentiation.

bioRxiv · Jul 23, 2020Cancer Biology